

LISTA DE LUCRĂRI ȘTIINȚIFICE

Conf. Dr. Cristina-Adela Iuga

Nr. Crt Publicație

1. Uifălean A, Rath H, Hammer E, Ionescu C. , Iuga CA*, Lalk M. Influence of soy isoflavones in breast cancer angiogenesis: a multiplex glass ELISA approach. JBUON. 23(6) (IN PRESS)
2. Uifalean A, Ilies M, Nicoara R, Rus LM, Heghes SC, Iuga CA. Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars. Pharmaceutics. 2018;10(4). [IF=3.746, Q1]
3. Pașcalău V, Dindelegan G, Dirzu N, Salantiu A, Pavel C, Dudescu MC, Popa F Borodi Gh, Tabaran F, Iuga CA, Popa C. Bioactive Ti-base biomaterial with sustained anti-bacterial response for endosseous applications. Reactive and Functional Polymers. 2018;125:37-46. [IF=2.975, Q2]
4. Ilies M, Sappa PK, Iuga CA, Loghin F, Gesell Salazar M, Weiss FU, et al. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer. Clin Chim Acta. 2018;477:127-34.[IF=2.926, Q2]
5. Hegheș SC, Gavrițaș LI, Pralea IE, Filip L, Cozma-Petruț A, Iuga CA, Suharoschi R, Miere D. Evaluation of energy and nutrient intake from food of lactating mothers in a romanian sample. 2018; Farmacia 66(2):243-47. [IF=1.507]
6. Iurian S, Dinte E, Iuga C, Bogdan C, Spiridon I, Barbu-Tudoran L, et al. The pharmaceutical applications of a biopolymer isolated from. Saudi Pharm J. 2017;25(8):1217-25. [IF=3.110, Q2]
7. Ilies M, Iuga CA, Loghin F, Dhople VM, Thiele T, Völker U, et al. Impact of blood sample collection methods on blood protein profiling studies. Clin Chim Acta. 2017;471:128-34. [IF=2.926, Q2]
8. Ilies M, Iuga CA, Loghin F, Dhople VM, Thiele T, Völker U, et al. Data on the impact of the blood sample collection methods on blood protein profiling studies. Data Brief. 2017;14:313-9.[BDI]
9. Ilies M, Iuga CA, Loghin F, Dhople VM, Hammer E. Plasma protein absolute quantification by nano-LC Q-TOF UDMS(E) for clinical biomarker verification. Clujul Med. 2017;90(4):425-30. [BDI]
10. Heghes SC, Rus LM, Rus LL, Bojita MT, Iuga CA. HPLC-UV determination of

LISTA DE LUCRĂRI ȘTIINȚIFICE

Conf. Dr. Cristina-Adela Iuga

- indapamide in the presence of its main synthesis and degradation impurities. Method validation. *Farmacia*. 2017;65(5):755-60. [IF=1.507]
11. Uifalean A, Schneider S, Gierok P, Ionescu C, Iuga CA, Lalk M. The Impact of Soy Isoflavones on MCF-7 and MDA-MB-231 Breast Cancer Cells Using a Global Metabolomic Approach. *Int J Mol Sci*. 2016;17(9). [IF=3.226, Q2]
 12. Uifalean A, Schneider S, Ionescu C, Lalk M, Iuga CA. Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future Perspectives. *Molecules*. 2016;21(1):E13. [IF=2.465, Q2]
 13. Uifalean A, Farcas A, Ilies M, Heghes SC, Ionescu C, Iuga CA. Assessment of isoflavone aglycones variability in soy food supplements using a validated HPLC-UV method. *Clujul Med*. 2015;88(3):373-80. [BDI]
 14. Ilieș M, Nicoară R, Uifălean A, Hegheș SC, Iuga CA, Loghin F. Perspectives to evaluate the impact of physical activity on mental health using a HPLC method for the monitoring of biogenic amine levels. *Palestrica of the third millennium – Civilization and Sport*. 2015;16(3):207-13. [BDI]
 15. Iuga C, Seicean A, Iancu C, Buiga R, Sappa PK, Volker U, et al. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma. *Proteomics*. 2014;14(7-8):945-55. [IF=3.807, Q1]
 16. Dinte E, Bodoki E, Leucuta SE, Iuga CA. Compatibility Studies between Drugs and Excipients in the Preformulation Phase of Buccal Mucoadhesive Systems. *Farmacia*. 2013;61(4):703-12. [IF=1.251]
 17. Thiele T, Sablewski A, Iuga C, Bakchoul T, Bente A, Gorg S, et al. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation - a LC-ESI-MS/MS-based proteomics approach. *Blood Transfusion*. 2012;10:S63-S70. [IF=1.858]
 18. Thiele T, Iuga C, Janetzky S, Schwertz H, Salazar MG, Furll B, et al. Early storage lesions in apheresis platelets are induced by the activation of the integrin alpha IIb beta(3) and focal adhesion signaling pathways. *Journal of Proteomics*. 2012;76:297-315. [IF=4.088, Q1]
 19. Suharoschi R, Iuga C, Crișan N, Pamfil D, Bălăcescu O, Muntean IL. A proposed curation protocol for discovery cancer potential biomarker candidates. *Agricultura – Știință și practică*. 2012;1-2(81-82):177-80. [BDI]

LISTA DE LUCRĂRI ȘTIINȚIFICE

Conf. Dr. Cristina-Adela Iuga

20. Rus LM, Tomuță I, Iuga C, Maier C, Kacso I, Borodi G, et al. Compatibility studies of indapamide/pharmaceutical excipients used in tablet preformulation. *Farmacia*. 2012;60(1):92-101. [IF=0.578]
21. Rus LM, Kacso I, Borodi G, Aluas M, Tomuță I, Iuga C, et al., editors. Solid form of indapamide recrystallized from acetonitrile/diethyl ether solvent mixture. *Processes in Isotopes and Molecules*; 2012; Melville: Amer Inst Physics. [ISI]
22. Muntean IL, Rotaru B, Suharoschi R, Iuga C, editors. Experiences in designing a distributed service-oriented platform for in-silico biomarker discovery and validation. *IEEE 12th International Conference on Bioinformatics & Bioengineering*; 2012. [ISI]
23. Szaniszló B, Iuga C, Bojiță M. Indirect determination of neomicin by derivative spectrophotometry. *Clujul Med*. 2011;84(3):398-401. [BDI]
24. Szaniszló B, Iuga C, Bojiță M. Indirect Determination of Gentamicin by Derivative Spectrophotometry. *Acta Medica Marisiensis*. 2011;57(5):516-8. [BDI]
25. Rus LM, Tomuță I, Iuga C, Maier C, Kacso I, Borodi G, et al. Indapamide slow release tablet preformulation: interactions with excipients analysis. *Clujul Med*. 2011;84(4):550-5. [BDI]
26. Achim M, Vlase L, Tomuta I, Muntean D, Iuga C, Georgescu R, et al. Preformulation studies for a parenteral solution of memantine. *Farmacia*. 2011;59(5):636-46. [IF=0.669]
27. Iuga C, Bojiță M. Stability study of omeprazole. *Farmacia*. 2010;58(2):203-10. [IF=0.850]
28. Bocșan CI, Major Z, Maier C, Pop R, Iuga C, Trifa A, et al. Study of the phenotypic variation expression in the metabolizing status of romanian epileptic patients. *Therapeutics, Pharmacology & Clinical Toxicology*. 2010;14(3):224-8. [BDI]
29. Iuga C, Bojiță M, Leucuța SE. Development of a validated RP-HPLC method for separation and determination of process-related Impurities of omeprazole in bulk drugs. *Farmacia*. 2009;57(5):534-41. [IF=0.144]
30. Iuga C, Moldovan M, Popa A, Leucuța SE. Validation of HPLC- UV method for analysis of omeprazole in presence of its metabolites in human plasma. *Farmacia*. 2008;56(3):254-60. [IF=0.064]

LISTA DE LUCRĂRI ȘTIINȚIFICE

Conf. Dr. Cristina-Adela Iuga

31. Achim M, Tomuta I, Vlase L, Iuga C, Moldovan M, Leucuta SE. Paclitaxel-loaded poly(lactic-co-glycolic acid) microspheres: preparation and in vitro evaluation. *Journal of Drug Delivery Science and Technology*. 2008;18(6):410-6.[IF=0.440]
32. Vlase L, Iuga C, Leucuța SE. Determinarea ciprofloxacinei din plasma umană prin HPLC cu detecție fluorimetrică. *Clujul Med*. 2006;79(3):473-8. [BDI]
33. Kiss B, Iuga C, Bojiță M. Therapeutic monitoring of rapamycine by High Performance Liquid Chromatography with ultraviolet detection. *Farmacia*. 2006;54(1):19-25. [BDI]
34. Kiss B, Iuga C, Bojiță M. Validation of an assay for determination of sirolimus in whole blood. *Timișoara Medical Journal*. 2005;55(5):209-11. [BDI]
35. Leucuța SE, Iuga C, Căpâlneanu R, Popa A, Leucuța A, Nanulescu M. Pharmacokinetic study of omeprazole in healthy volunteers. *Clujul Med*. 2004;77(2):381-5. [BDI]
36. Leucuța A, Farcău D, Iuga C, Draghiciu D, Nanulescu M, Leucuța SE. Compartmental and non-compartmental pharmacokinetics of omeprazole in adults and children. *Terapeutică, Farmacologie și Toxicologie clinică*. 2004;8(2):100-3. [BDI]
37. Imre S, Bojiță M, Făgărășan E, Filip L, Iuga C, Muntean D. Testarea accelerată a stabilității unor antiemetice. *Clujul Med*. 2003;(76):1. [BDI]
38. Leucuța SE, Iuga C, Vlase L, Popa DS, Căpâlneanu R, Popa A, et al. Bioavailability of a generic formulation of loratadine compared with the reference tablet dosage form. *Farmacia*. 2003;51(4):30-9. [BDI]
39. Leucuța SE, Iuga C, Căpâlneanu R, Popa A, Preda M, Rusu A. Pharmacokinetics and bioavailability of rifampicine, desacetylrifampicine and isoniazide in healthy volunteers. *Terapeutică, Farmacologie și Toxicologie clinică*. 2003(7):1.
40. Imre S, Marin Saez R, Făgărășan E, Iuga C, Bojiță M, Filip L. Comparison of a spectrophotometric assay of a mixture with a chromatographic method. *Bulletin of the University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca Food Science and Technology*. 2002;59(2):194-201. [BDI]
41. Leucuța SE, Iuga C, Căpâlneanu R, Popa A, Preda M. Bioequivalence evaluation of two pharmaceutical formulation with omeprazole: Omeran (Europharm) versus

LISTA DE LUCRĂRI ȘTIINȚIFICE

Conf. Dr. Cristina-Adela Iuga

- Losec (Astra). Terapeutică, Farmacologie și Toxicologie clinică 2002;6(3):101-3. [BDI]
42. Moldovan M, Iuga C, Leucuța SE. Influence of hidrocortizone acetate distribution in-between oil/water phases on "in vitro" difusion and dermal bioavailability. Farmacia. 2001;49(5):31-40. [BDI]
 43. Iuga C, Bojiță M, Marin Saez R, Imre S. Comparative study of apparent content curves method (CCA) and HPLC method applied for resolution of binary mixture omeprazole-metocloprami. Farmacia. 2001;49(3):45-52. [BDI]
 44. Hudrea F, Grosset C, Alary J, Bojiță M, Iuga C, Miron M. Etude de stabilité d'Euciprin gelules contenant 250 mg ciprofloxacine. Farmacia. 1999;57(1):35-43. [BDI]
 45. Iuga C, Bojiță M, Hudrea F, Miron M. Determinarea catitativă a omeprazolului prin fotodensitometrie. Farmacia. 1999;57(1):25-34. [BDI]
 46. Hudrea F, Bojiță M, Alary J, Iuga C, Miron M. Date privind comportarea cromatografică a ciprofloxacinei. Farmacia. 1997;45(3):47-53. [BDI]
 47. Iuga C, Bojiță M, Hudrea F, Miron M. Contribuții la dozarea omeprazolului ca atare și din forme farmaceutice. Farmacia. 1997;45(4):43-51. [BDI]